CHMP recommends guidance to manage risk of PML with Biogen's Tysabri
This article was originally published in Scrip
Executive Summary
The EU's CHMP has recommended additional measures to be taken to mitigate the risk developing progressive multifocal leucoencephalopathy (PML) in patients with relapsing-remitting multiple sclerosis who are receiving treatment with Biogen Idec/Elan's Tysabri (natalizumab).